마이코플라스마 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품별, 기술별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Mycoplasma Testing Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Product, By Technology, By Application, By End-User, By Region, Competition, 2020-2030F
세계의 마이코플라스마 검사 시장은 2024년에 10억 9,070만 달러에 달하며, 2030년까지 CAGR은 13.45%로 견고한 성장이 예측됩니다. 세계 마이코플라즈마 검사 시장은 진단 및 감염 관리라는 광범위한 분야 중 역동적이고 빠르게 발전하고 있는 분야입니다. 마이코플라즈마는 세포벽이 없는 것으로 알려진 박테리아 속이며, 인간, 동물, 세포배양을 포함한 다양한 숙주 생물을 감염시킵니다. 마이코플라즈마 오염은 연구, 바이오의약품 제조 및 임상 진단에 심각한 위협이 될 수 있으므로 마이코플라즈마 검사는 품질관리 및 안전 보증에 필수적인 요소입니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
10억 9,070만 달러 |
| 시장 규모 : 2030년 |
23억 3,062만 달러 |
| CAGR: 2025-2030년 |
13.45% |
| 급성장 부문 |
키트 및 시약 |
| 최대 시장 |
북미 |
주요 시장 성장 촉진요인
바이오의약품 및 바이오테크놀러지 산업의 성장
주요 시장 과제
개발도상국의 비용 제약
주요 시장 동향
분자진단의 급속한 보급
세계 마이코플라즈마 검사 시장의 중요한 동향 중 하나는 분자진단, 특히 중합효소 연쇄반응(PCR) 기반 방법의 급속한 채택입니다.
목차
제1장 제품 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 제품별(기기, 키트, 시약)
- 기술별(PCR, ELISA, 효소법, DNA 염색, 기타)
- 용도별(세포주 시험, 바이오프로덕션 시험, 기타)
- 최종사용자별(학술연구기관, 세포은행, 계약 조사기관, 제약·바이오테크놀러지 기업, 기타)
- 지역별
- 기업별(2024년)
- 시장 맵
제6장 북미의 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 북미 : 국가별 분석
제7장 유럽의 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 아시아태평양 : 국가별 분석
제9장 남미의 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 마이코플라스마 검사 시장 전망
- 시장 규모·예측
- 시장 점유율·예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 마이코플라스마 검사 시장 : SWOT 분석
제14장 경쟁 구도
- Agilent Technologies Inc
- ATCC
- Bionique Testing Laboratories Inc.
- Charles River Laboratories International Inc.
- Lonza Group Ltd
- Merck KGaA
- Bionique Testing Laboratories Inc.
- PromoCell GmbH
- Thermo Fisher Scientific Inc.
- Sartorius AG
제15장 전략적 제안
제16장 조사회사 소개·면책사항
KSA
Global Mycoplasma Testing Market was valued at USD 1090.70 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 13.45% through 2030. The Global Mycoplasma Testing Market is a dynamic and rapidly evolving sector within the broader field of diagnostics and infectious disease management. Mycoplasma, a genus of bacteria known for their lack of a cell wall, can infect various host organisms, including humans, animals, and cell cultures. Mycoplasma contamination poses a significant threat to research, biopharmaceutical manufacturing, and clinical diagnostics, making mycoplasma testing an essential component of quality control and safety assurance.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 1090.70 Million |
| Market Size 2030 | USD 2330.62 Million |
| CAGR 2025-2030 | 13.45% |
| Fastest Growing Segment | Kits and Reagents |
| Largest Market | North America |
Key Market Drivers
Rising Biopharmaceutical and Biotechnology Industries
The rapid expansion of the biopharmaceutical and biotechnology industries is a key driver of the Global Mycoplasma Testing Market. Over the past few years, the number of FDA-registered manufacturing facilities in the U.S. producing human-use medicines, along with their associated testing, labeling, and packaging operations, has surged by more than 50%. Biopharmaceutical companies are actively investing in new construction, facility expansions, and technology upgrades to support the production of next-generation therapies, ensuring a robust and scalable supply chain for advanced treatments across the country. These industries rely heavily on cell culture-based production processes, where contamination can compromise product integrity, regulatory compliance, and patient safety. Mycoplasma, a frequent and insidious contaminant, necessitates stringent testing protocols to ensure the purity and efficacy of biopharmaceutical products. The rising investments, increasing adoption of biologics, and growing need for quality control in biotech processes directly fuel the demand for mycoplasma testing. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and biosimilars, are revolutionizing modern medicine. These products rely on mammalian cell cultures for production, making them highly susceptible to mycoplasma contamination. The growing adoption of biologics for treating chronic diseases, including cancer, autoimmune disorders, and infectious diseases, necessitates stringent contamination control measures. As patents for biologic drugs expire, biosimilar manufacturers must comply with regulatory guidelines for mycoplasma testing to ensure their products meet the same safety and efficacy standards as originator biologics. With global sales of biologics projected to surpass traditional pharmaceuticals, mycoplasma testing has become an integral part of quality assurance in drug development and production.
Key Market Challenges
Cost Constraints in Developing Regions
One of the significant challenges in expanding the mycoplasma testing market is the cost associated with acquiring and implementing testing solutions. In developing regions with limited healthcare budgets, investing in expensive mycoplasma testing equipment and reagents can be prohibitive.
Many developing countries allocate a substantial portion of their healthcare budgets to basic healthcare needs like vaccinations and infectious disease control. This leaves limited resources for advanced diagnostic technologies, including mycoplasma testing. Establishing a mycoplasma testing infrastructure, including purchasing specialized equipment and training personnel, requires a considerable initial investment that some regions may struggle to afford. Continuous testing relies on a steady supply of costly reagents and consumables, which can be a financial burden for healthcare facilities in resource-constrained areas.
Key Market Trends
Rapid Adoption of Molecular Diagnostics
One significant trend in the Global Mycoplasma Testing Market is the rapid adoption of molecular diagnostics, particularly Polymerase Chain Reaction (PCR)-based methods.
Molecular diagnostic techniques, such as PCR, offer unparalleled sensitivity and specificity in detecting mycoplasma DNA. They can identify even low levels of contamination quickly and accurately. Molecular tests provide rapid results, often within hours, compared to traditional culture-based methods that can take days or even weeks. This speed is crucial in maintaining the efficiency of biopharmaceutical production and research. Automated molecular testing platforms allow for high throughput, making them suitable for large-scale testing in biopharmaceutical manufacturing facilities. PCR-based methods reduce the risk of false positives associated with traditional culture-based techniques, as they do not rely on the growth of mycoplasma cells.
Key Market Players
- Agilent Technologies Inc
- ATCC
- Bionique Testing Laboratories Inc.
- Charles River Laboratories International Inc.
- Lonza Group Ltd
- Merck KGaA
- Bionique Testing Laboratories Inc.
- PromoCell GmbH
- Thermo Fisher Scientific Inc.
- Sartorius AG
Report Scope:
In this report, the Global Mycoplasma Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Mycoplasma Testing Market, By Product:
- Instruments
- Kits and Reagents
Mycoplasma Testing Market, By Technology:
- PCR
- ELISA
- Enzymatic Methods
- DNA Staining
- Other
Mycoplasma Testing Market, By Application:
- Cell Line Testing
- Bioproduction Testing
- Other
Mycoplasma Testing Market, By End-User:
- Academic Research Institutes
- Cell Banks
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Others
Mycoplasma Testing Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.
Available Customizations:
Global Mycoplasma Testing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Mycoplasma Testing Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Product (Instruments, Kits and Reagents)
- 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
- 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
- 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)
- 5.2.5. By Region
- 5.2.6. By Company (2024)
- 5.3. Market Map
6. North America Mycoplasma Testing Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Product
- 6.2.2. By Technology
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Mycoplasma Testing Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Product
- 6.3.1.2.2. By Technology
- 6.3.1.2.3. By Application
- 6.3.1.2.4. By End User
- 6.3.2. Canada Mycoplasma Testing Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Product
- 6.3.2.2.2. By Technology
- 6.3.2.2.3. By Application
- 6.3.2.2.4. By End User
- 6.3.3. Mexico Mycoplasma Testing Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Product
- 6.3.3.2.2. By Technology
- 6.3.3.2.3. By Application
- 6.3.3.2.4. By End User
7. Europe Mycoplasma Testing Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Technology
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Mycoplasma Testing Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Technology
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. United Kingdom Mycoplasma Testing Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Technology
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. Italy Mycoplasma Testing Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Technology
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 7.3.4. France Mycoplasma Testing Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Product
- 7.3.4.2.2. By Technology
- 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain Mycoplasma Testing Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Product
- 7.3.5.2.2. By Technology
- 7.3.5.2.3. By Application
- 7.3.5.2.4. By End User
8. Asia-Pacific Mycoplasma Testing Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Technology
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Mycoplasma Testing Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Technology
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. India Mycoplasma Testing Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Technology
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. Japan Mycoplasma Testing Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Technology
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. South Korea Mycoplasma Testing Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Technology
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Australia Mycoplasma Testing Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Technology
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
9. South America Mycoplasma Testing Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Technology
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Mycoplasma Testing Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Technology
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Mycoplasma Testing Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Technology
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Mycoplasma Testing Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Technology
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
10. Middle East and Africa Mycoplasma Testing Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Technology
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Mycoplasma Testing Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Technology
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Mycoplasma Testing Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Technology
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. UAE Mycoplasma Testing Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Technology
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. Global Mycoplasma Testing Market: SWOT Analysis
14. Competitive Landscape
- 14.1. Agilent Technologies Inc
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. ATCC
- 14.3. Bionique Testing Laboratories Inc.
- 14.4. Charles River Laboratories International Inc.
- 14.5. Lonza Group Ltd
- 14.6. Merck KGaA
- 14.7. Bionique Testing Laboratories Inc.
- 14.8. PromoCell GmbH
- 14.9. Thermo Fisher Scientific Inc.
- 14.10.Sartorius AG
15. Strategic Recommendations
16. About Us & Disclaimer
